With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33100-27-5,1,4,7,10,13-Pentaoxacyclopentadecane,as a common compound, the synthetic route is as follows.
General procedure: Crystals of compounds 1?3 were prepared by isothermal evaporation fromaqueous solutions at room temperature. The crystals of compound 1 weresynthesized by the reaction of 0.051 g (0.1 mmol) of UO2(NO3)2¡¤6H2O,0.040 g (0.22 mmol) of 12-crown-4, 0.280 g (2.0 mmol) of 40percent H2SeO4,and 2.001 g (111.2 mmol) of deionized distilled water. Compound 2:0.050 g (0.1 mmol) of uranyl nitrate, 0.046 g (0.21 mmol) of 15-crown-5,0.282 g (2.0 mmol) of selenic acid, and 2.012 g (111.7 mmol) of deionizeddistilled water. Compound 3: 0.050 g (0.1 mmol) of uranyl nitrate, 0.046 g(0.21 mmol) of 15-crown-5, 0.282 g (2.0 mmol) of selenic acid, and 2.012 g(111.7 mmol) of deionized distilled water (note: the bulk of crystals herebelongs to compound 2). Homogeneous liquid solutions were left in awatch glass. Yellowish-green flattened crystals formed within 2 weeks.
The synthetic route of 33100-27-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Article; Gurzhiy, Vladislav V.; Tyumentseva, Olga S.; Tyshchenko, Darya V.; Krivovichev, Sergey V.; Tananaev, Ivan G.; Mendeleev Communications; vol. 26; 4; (2016); p. 309 – 311;,
Chiral Catalysts
Chiral catalysts – SlideShare